Updates are available Correction dated 2023-10-11
Click to view Correction: https://doi.org/10.1038/s41590-023-01674-z
-
Authors
Son, Aran
Meylan, Francoise
Gomez-Rodriguez, Julio
Kaul, Zenia http://orcid.org/0000-0002-3123-8164
Sylvester, McKella
Falduto, Guido H.
Vazquez, Estefania
Haque, Tamara
Kitakule, Moses M.
Wang, Chujun
Manthiram, Kalpana http://orcid.org/0000-0001-6451-8173
Qi, Chen-Feng
Cheng, Jun
Gurram, Rama K.
Zhu, Jinfang
Schwartzberg, Pamela http://orcid.org/0000-0001-6318-9187
Milner, Joshua D. http://orcid.org/0000-0002-3913-3869
Frischmeyer-Guerrerio, Pamela A.
Schwartz, Daniella M. http://orcid.org/0000-0002-1660-8438
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (ZIA-AI001202; ZIA-AI001202; ZIA-AI001098; ZIA-AI001240, ZIA-AI001251, ZIA-AI001251, ZIA-AI001240, ZIA-AI001251, ZIA-AI001240, ZIA-AI001251, ZIA-AI001098, ZIA-AI001202, ZIA-AI001202)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (ZIC-AR041181)
University of Pittsburgh start-up funding
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
- License Information
-
More Information
Article History
Received: 1 April 2022
Accepted: 27 March 2023
First Online: 27 April 2023
Change Date: 11 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-023-01674-z
Competing interests
: J.G.-R. is currently employed by TCR Therapeutics. F.M. has been recruited by AstraZeneca and was very briefly employed by Innovent Biologics. All other authors have no competing interests.
